Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PASylated uricase
- Development stage
- Preclinical
- Lead developer
- XL-protein
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
PASylated uricase is a recombinant fusion protein consisting of the enzyme urate oxidase (uricase), typically derived from *Aspergillus flavus*, genetically fused with PAS (proline-alanine-serine) polypeptide sequences. This modification is designed to increase the enzyme's plasma half-life and stability while reducing immunogenicity, serving as a biodegradable alternative to PEGylation technology. The enzyme works by catalyzing the oxidation of uric acid into the more soluble and easily excreted compound allantoin. It is primarily being investigated for the treatment of conditions associated with high uric acid levels, including severe gout, hyperuricemia, chemotherapy-induced hyperuricemia, and tumor lysis syndrome. Among the variants, UOX-PAS100 has demonstrated the most significant improvements in half-life and catalytic efficiency compared to the native enzyme.
- Other names
- PAS-uricasePASylated urate oxidase
Beyond the preview
Go deeper on PASylated uricase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PASylated uricase.